^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners

    TEST:
    AlphaLiquid® Detect

    Company:
    IMBdx
    Type:
    Laboratory Developed Test
    Related tests:
    Details
    Evidence

    News

    20d
    Analytical validation of a hybrid-approach combining tumor-informed and tumor-agnostic bespoke ctDNA panel assay for the sensitive detection of minimal residual disease. (PubMed, PLoS One)
    The CancerDetectTM is a hybrid-approach MRD test combining both personalized (bespoke) mutations and tumor-agnostic clinically actionable targets (hotspot mutations) with hybridization capture technology. The analytical validation result of CancerDetectTM showed limit of detection successfully reached down to 0.001% (10-5) with 99.9% specificity.
    Journal • Pan tumor • Minimal residual disease • Circulating tumor DNA
    |
    AlphaLiquid® Detect
    2years
    Personalized circulating tumor DNA assay precisely predicts the response of neoadjuvant chemotherapy in breast cancer patients (SABCS 2023)
    In addition, ctDNA at curative surgery also can predict NAC response in EBC patients. Long term ctDNA follow up of MRD would be warranted.
    Clinical • Circulating tumor DNA
    |
    HER-2 (Human epidermal growth factor receptor 2)
    |
    HER-2 positive • HR positive
    |
    AlphaLiquid® Detect